BBR enhances CRC's resistance to chemotherapy by downregulating anti-NF-κB (Yu et al., 2014) and may also inhibit CRC cells' resistance to targeted drugs (Su et al., 2015). This evidence concerns the gene NFKB1 and colorectal carcinoma.